Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness

Expert Rev Clin Immunol. 2019 Mar;15(3):241-250. doi: 10.1080/1744666X.2019.1562903. Epub 2019 Feb 4.

Abstract

Anti-DFS70 antibodies and their clinical associations remain an immunological paradox. Unlike other antinuclear antibodies (ANA), there is a growing body of evidence that anti-DFS70 antibodies, when present in high titers and in isolation (without accompanying other antibodies), are useful to aid in the exclusion of ANA associated rheumatic diseases. Areas covered: This review aims to analyze and interpret the current published knowledge and recent findings to provide guidance in the use of anti-DFS70 antibodies to analyze associations of this unique autoantibody. Expert commentary: Although the association of anti-DFS70 antibodies is still unknown, their use as a biomarker that can aid in the exclusion of ANA related diseases is well-established.

Keywords: ANA; ANA associated rheumatic disease; Autoantibodies; anti-DFS70; antinuclear antibodies; dense fine speckled; indirect immunofluorescence.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Adaptor Proteins, Signal Transducing / immunology*
  • Antibodies, Antinuclear / immunology*
  • Autoantigens / immunology
  • Biomarkers / analysis
  • Humans
  • Rheumatic Diseases / immunology*
  • Transcription Factors / immunology*

Substances

  • Adaptor Proteins, Signal Transducing
  • Antibodies, Antinuclear
  • Autoantigens
  • Biomarkers
  • PSIP1 protein, human
  • Transcription Factors